Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
- Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317-1330.
- Meletios A. Dimopoulos, Delimpasi S, et al. Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: initial results of the phase III BOSTON study. J Clin Oncol. 2020;38(suppl 15):8501.
- Selinexor and backbone treatments of multiple myeloma patients (STOMP). ClinicalTrials.gov identifier: NCT02343042. Updated August 21, 2020. Accessed October 27, 2020. https://www.clinicaltrials.gov/ct2/show/NCT02343042
Disclosure statements are available on the authors' profiles: